En las personas con macroprolactinoma fue de 65 meses, con mediana de dosis acumulada de CAB de mg. Se requieren estudios prospectivos para aclarar si la dosis acumulada es un factor predictor para aumentar el porcentaje de pacientes con retiro exitoso y establecer la mejor estrategia para retiro de agonistas de dopamina en pacientes con prolactinomas. Methodology: Case series. Demographic and clinical variables were described, as well as radiological monitoring once yearly and basal prolactin PRL measurements at 6 and 24 months.

Author:Kimi Kashura
Language:English (Spanish)
Published (Last):2 December 2017
PDF File Size:6.24 Mb
ePub File Size:14.41 Mb
Price:Free* [*Free Regsitration Required]

Hyperprolactinemia is a frequent neuroendocrinological condition that should be approached in an orderly and integral fashion, starting with a complete clinical history. Once physiological causes such as pregnancy, systemic disorders such as primary hypothyroidism and the use of drugs with dopamine antagonistic actions such as metochlopramide have been ruled out, the most common cause of hyperprolactinemia is a PRL-secreting pituitary adenoma or prolactinoma.

Prolactinomas are usually classified as microprolactinomas less than 1 cm or macroprolactinomas larger than 1 cm , which can either be confined or invasive. Macroprolactinomas can also present with symptoms and signs resulting form mass effect of the tumor, such as headaches and visual field defects. Other structural causes of hyperprolactinemia include non-functioning pituitary adenomas and infiltrative disorders, which can interrupt the inhibitory, descending dopaminergic tone.

The primary treatment of prolactinomas is pharmacological with dopamine agonists such as cabergoline.

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. Search: Search. Advanced Clipboard. Create file Cancel. Email citation To:. Format: Summary Summary text Abstract Abstract text. Send email Cancel. Add to Collections Create a new collection Add to an existing collection. Name your collection: Name must be less than characters.

Choose a collection: Unable to load your collection due to an error Please try again. Add Cancel. Add to My Bibliography My Bibliography. Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:.

Search terms:. Test search terms. Would you like email updates of new search results? Email: change. Frequency: Monthly Weekly Daily. Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items.

Send even when there aren't any new results. Optional text in email:. Save Cancel. Create a file for external citation management software Create file Cancel. Cite Favorites. Abstract in English , Spanish. Similar articles Hyperprolactinemia: pathophysiology and management. Verhelst J, Abs R. Verhelst J, et al. Treat Endocrinol. PMID: Review. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. Colao A, et al. N Engl J Med. PMID: Diagnostic evaluation of hyperprolactinemia.

Biller BM. J Reprod Med. Glezer A, Bronstein MD. Glezer A, et al. Arq Bras Endocrinol Metabol. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.

Vilar L, et al. Arch Endocrinol Metab. Show more similar articles See all similar articles. Elsersy MAM. J Obstet Gynaecol India.

Epub Jun Kanasaki H, et al. Int J Mol Sci. Publication types Review Actions. Cabergoline Actions. Humans Actions. Substances Dopamine Agonists Actions. Ergolines Actions. LinkOut - more resources Medical Genetic Alliance. Copy Download.



Although this distinction is largely arbitrary, it is commonly used and does highlight an important fact: small intrapituitary lesions microadenomas present differently and have different surgical and imaging challenges from larger lesions macroadenomas that extend into the suprasellar region. This article is a general overview. Pituitary adenomas are common, with rates varying widely depending on the definition: population prevalence is approximately 0. Pituitary adenomas present either due to hormonal imbalance both microadenomas and macroadenomas or mass effect on adjacent structures macroadenomas , classically the optic chiasm. Rarely presentation can be catastrophic, due to pituitary apoplexy. Over half of all adenomas are secretory 2 , although even when this is the case this may not be the cause of presentation. A lack of libido or even galactorrhea may not lead to presentation and as such many secreting tumors are only diagnosed when mass effect occurs see below.


Tratamiento del Tumor de la HipĆ³fisis

These images are a random sampling from a Bing search on the term "Pituitary Adenoma. Search Bing for all related images. Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. Pituitary tumors are common, but often they don't cause health problems. Most people with pituitary tumors never even know they have them.

Related Articles